Bio-Connect
Product image
Product image
Product image

InVivoMAb anti-human PD-1 (CD279)

Research Use Only
BE0188
Bio X Cell
ApplicationsNeutralisation/Blocking
Product group Antibodies
ReactivityHuman
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoMAb anti-human PD-1 (CD279)
  • Delivery Days Customer
    7
  • Applications
    Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    J116
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Mouse
  • Isotype
    IgG1
  • Scientific Description
    The J116 monoclonal antibody reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. Binding of the J116 antibody is reported to inhibit PD-1 signal transduction, however, it is not reported to block PD-L1 binding.
  • Reactivity
    Human
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Programmed death-1 controls T cell survival by regulating oxidative metabolism. Tkachev V et al., 2015 Jun 15, J Immunol
    Read more
  • The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Tsukahara T et al., 2015 Feb, Gene Ther
    Read more
  • Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Wang C et al., 2013 Apr, J Clin Invest
    Read more
  • Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-gamma producing T cells. Singh A et al., 2012, PLoS One
    Read more
  • Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Rosignoli G et al., 2009 Jul, Clin Exp Immunol
    Read more
  • Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. Jurado JO et al., 2008 Jul 1, J Immunol
    Read more

Related products

Product image
Product group Antibodies
References
Bio X Cell
  • SizePrice
Product image
Product group Chemicals
Bio X Cell
  • SizePrice